SHOCKING: Abbott | Mind Blowing Facts

Abbott Agrees to Pay Nearly $385 Million Over Infant Formula Manufacturing Allegations

Abbott Laboratories has agreed to pay nearly $385 million to settle federal and state allegations involving the manufacture of certain powder infant formula and nutritional therapy products, including products purchased through government-funded nutrition programs.

Clever Dude · Sep 22

Beta Bionics Wins FDA Clearance for Mint Tubeless Insulin Patch Pump, Plans Pharmacy-Only U.S. Launch in Early 2027

The FDA cleared Beta Bionics' Mint tubeless insulin patch pump. What the clearance covers, when it launches, and what people with diabetes should know.

Medical Daily · Sep 16

Abbott Agrees to Pay Nearly $385 Million to Settle Claims Over Infant Formula Made in Michigan and Arizona

Abbott will pay $384,999,040 to settle False Claims Act allegations over infant formula from its Sturgis and Casa Grande plants. What parents should know.

Medical Daily · Sep 16

Abbott Stock: Is Wall Street Bullish or Bearish?

Abbott has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Barchart · Aug 6

New blood test to detect colon cancer clears FDA approval

New cases of colorectal cancer and deaths have been rising in younger adults since the mid-2000s

The Independent UK · Aug 3

FDA Approves a Blood Test for Colorectal Cancer Screening That Misses Most Precancerous Growths

The FDA approved SimpleScreen CRC, a blood test for colorectal cancer screening. It detects cancer well but finds few precancerous lesions.

Medical Daily · Jul 30

This Dividend King Could Be One of the Safest Stocks to Own Right Now

Abbott's diversified healthcare business is one of the main reasons why it remains a reliable dividend stock.

Barchart · Jul 20

Trump DOJ Drops Corporate Crime Investigations, Giving Major Companies a Free Pass

The Trump Justice Department has dropped several high-profile corporate investigations, including an inquiry into Federal Reserve Chair Jerome Powell, fueling concerns over a pullback in enforcement.

International Business Times UK · Jul 20

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.

MarketBeat · Jul 16

Abbott Labs shares jump 12% as Q2 sales rise, profit outlook raised

Abbott Laboratories shares surged 12% after the healthcare company reported strong second-quarter sales, raised its full-year earnings outlook and reaffirmed revenue growth guidance. Progress across its medical devices and diagnostics pipeline further boosted investor confidence in future growth.

The Economic Times · Jul 16